FDA update on AstraZeneca heartburn drugs and Heart Failure

WASHINGTON (Reuters) - U.S. regulators are likely to update the public within days about any potential heart risks of AstraZeneca Plc's stomach-acid drugs, which are taken by more than 1 billion people worldwide.

In early August, the U.S. Food and Drug Administration and Health Canada said they were studying the cardiac impact of Prilosec and Nexium.

The agencies at the time cited two studies suggesting an association with greater risk of heart attacks, heart failure and heart-related sudden death when compared with surgery. However, the FDA's own initial analyses did not show a higher heart risk, and both agencies told doctors not to change prescribing practices.

The FDA, which regulates the world's biggest drug market, said it would give more definitive advice in three months. An agency spokeswoman declined to comment.

The "early communication" is part of a new FDA effort to notify the public and doctors sooner about potential drug risks. It comes after criticism of a slow response in dealing with Merck & Co's now-recalled Vioxx painkiller and safety fears tied to GlaxoSmithKline's Avandia treatment for diabetes.

Nexium is AstraZeneca's top-selling product and was the world's No. 2 best-selling drug in the world in 2006, according to pharmaceutical information firm IMS Health. AstraZeneca reported $5.2 billion in Nexium sales for last year.

The company and Procter & Gamble Co, which sells over-the-counter Prilosec, have said they agreed with the FDA's early assessment of no risk.

"These patients have two common problems: a need for (a Prilosec-type drug), and heart disease," said Dr. Michael Weinstein, who is on the board of the American Gastroenterology Association. "Both are very common, and the fact that they occasionally occur together is not surprising." Continued...